PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Show full item record




Ali , A S , Langer , S W , Federspiel , B , Hjortland , G O , Gronbaek , H , Ladekarl , M , Welin , S , Vestermark , L W , Arola , J , Osterlund , P , Knigge , U , Sorbye , H , Micke , P , Grimelius , L , Gronberg , M & Janson , E T 2020 , ' PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3 ' , PLoS One , vol. 15 , no. 12 , 0243900 . https://doi.org/10.1371/journal.pone.0243900

Title: PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Author: Ali, Abir Salwa; Langer, Seppo W.; Federspiel, Birgitte; Hjortland, Geir Olav; Gronbaek, Henning; Ladekarl, Morten; Welin, Staffan; Vestermark, Lene Weber; Arola, Johanna; Osterlund, Pia; Knigge, Ulrich; Sorbye, Halfdan; Micke, Patrick; Grimelius, Lars; Gronberg, Malin; Janson, Eva Tiensuu
Other contributor: University of Helsinki, HUSLAB
University of Helsinki, HUS Comprehensive Cancer Center

Date: 2020-12-14
Language: eng
Number of pages: 12
Belongs to series: PLoS One
ISSN: 1932-6203
DOI: https://doi.org/10.1371/journal.pone.0243900
URI: http://hdl.handle.net/10138/324921
Abstract: Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.
3122 Cancers
3111 Biomedicine

Files in this item

Total number of downloads: Loading...

Files Size Format View
pone.0243900.pdf 2.780Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record